SEER Seer

Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum

Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum

REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the upcoming Canaccord MedTech, Diagnostics and Digital Health and Services Forum in New York, NY.

Seer’s management is scheduled to present on Thursday, November 16th at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.

About Seer

Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit .

Investor Inquiries:

Carrie Mendivil

Media Inquiries:

Consort Partners



EN
10/11/2023

Underlying

SEERSeer

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Seer

 PRESS RELEASE
Free
SEER SEER

Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Ad...

Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026 Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights REDWOOD CITY, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation in the 2026 U.S. Human Proteome Organization (US HUPO) Annual Conference, taking place February 21-25 in St. Louis, Missouri. At ...

February 19, 2026 1 EN
 PRESS RELEASE
Free
SEER SEER

Seer to Participate in the TD Cowen 46th Annual Health Care Conference

Seer to Participate in the TD Cowen 46th Annual Health Care Conference REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Seer’s management is scheduled to participate in a fireside chat on Wednesday, March 4th at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s website at inve...

February 18, 2026 1 EN
 PRESS RELEASE
Free
SEER SEER

Seer to Report Fourth Quarter and Full Year 2025 Financial Results on ...

Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the fourth quarter and full year 2025 on Thursday, February 26, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio...

February 5, 2026 1 EN
 PRESS RELEASE
Free
SEER SEER

Nature Genetics Study Validates Seer’s Proteograph Platform as Essenti...

Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers Large-scale GWAS across ~1,600 samples shows how peptide-level mass spectrometry distinguishes true protein changes from potential binding artifacts resulting from affinity-based approaches, establishing accuracy as the foundation for downstream discovery REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the publication in Natur...

December 1, 2025 1 EN
 PRESS RELEASE
Free
SEER SEER

Seer and Collaborators Unveil Broad New Data Demonstrating the Transla...

Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025 Studies spanning cardiovascular, aging, and cancer biology highlight how Seer’s Proteograph® platform is enabling discovery at population scale REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced new data to be featured at the Human Proteome Organization (HUPO) World Congress 2025, underscoring how deep, scalable proteomics is transforming the study of human...

November 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch